Company News »

Detailed Results from Biogen Idec and AbbVie’s Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTATM (Daclizumab High-Yield Process)

Business Wire
Share on StockTwits
Published on
Share on StockTwits